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Abstract
The purpose of this study is to determine the methylation status of Transforming growth factor-beta-inducible
gene-h3 (TGFBI) and its correlation with paclitaxel chemoresistance in ovarian cancer. The methylation status of
TGFBI was examined in ovarian cancer and control groups by methylation-specific PCR (MSP) and bisulfite
sequencing PCR (BSP). The TGFBI expression and cell viability were compared by Quantitative Real-Time PCR,
Western Blotting and MTT assay before and after demethylating agent 5-aza-2’-deoxycytidine (5-aza-dc) treatment
in 6 cell lines (SKOV3, SKOV3/TR, SKOV3/DDP, A2780, 2780/TR, OVCAR8). In our results, TGFBI methylation was
detected in 29/40 (72.5%) of ovarian cancer and 1/10 (10%) of benign ovarian tumors. No methylation was
detected in normal ovarian tissues (P < 0.001). No statistical correlation between RUNX3 methylation and
clinicopathological characteristics was observed. A significant correlation between TGFBI methylation and loss of
TGFBI mRNA expression was found (P < 0.001). The methylation level of TGFBI was significantly higher in paclitaxel
resistant cell lines (SKOV3/TR and 2780/TR) than that in the sensitive pairs (P < 0.001). After 5-aza-dc treatment, the
relative expression of TGFBI mRNA and protein increased significantly in SKOV3/TR and A2780/TR cells. However,
no statistical differences of relative TGFBI mRNA expression and protein were found in other cells (all P > 0.05),
which showed that re-expression of TGFBI could reverse paclitaxel chemoresistance. Our results show that TGFBI is
frequently methylated and associated with paclitaxel-resistance in ovarian cancer. TGFBI might be a potential
therapeutic target for the enhancement of responses to chemotherapy in ovarian cancer patients.
Keywords: Ovarian cancer, transforming growth factor-beta-inducible gene-h3, methylation, chemoresistance,
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Introduction
Epithelial ovarian cancer is the most lethal gynecologic
malignancy, with 21 990 estimated new cases and 15
460 deaths in the USA in 2011 [1]. Reasons for this
high lethality include the advanced stage at which
patients are diagnosed and the inherent aggressive biol-
ogy of this cancer.
Maximal surgical cytoreduction followed by systemic
chemotherapy with carboplatin and paclitaxel is the cur-
rent standard treatment modality for advanced ovarian
cancer [2]. A key feature of ovarian cancer is its sensitiv-
ity to chemotherapeutic drugs such as paclitaxel, a pro-
totype taxane, stabilizes microtubule polymers leading to
mitotic arrest and apoptosis [3]. Unfortunately, ovarian
cancer cells, with their unstable genomes [4], are initially
sensitive to these drugs, but long term utilization may
result in the chemoresistance [5].
Epigenetic alterations play an important role in the
initiation and progression of cancer [6-8]. Hypermethy-
lation of CpG rich islands in promoter regions of genes
has been characterized as a common epigenetic altera-
tion for the silencing or inactivation of tumor suppres-
sor genes and transcriptional repression in human
malignancies [9,10], including ovarian cancer [11-13]. In
recent years, emerging evidence has also linked epige-
netic changes to the development of drug resistance
[14,15].
Transforming growth factor-beta-inducible gene-h3
(TGFBI) is a secreted protein first identified in a human
lung adenocarcinoma cell line treated with transforming
growth factor-b [16]. It has been shown to possess
tumor suppressor function in vitro studies [17,18], and
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by inducing stabilization of microtubules via integrin-
mediated signaling pathways [19]. Recently, promoter
hypermethylation of TGFBI was found in lung [20,21]
and prostate cancer [20]. However, the role of TGFBI
methylation in paclitaxel chemoresistance in ovarian
cancer is unknown. Therefore, a better understanding of
this epigenetic mechanism of TGFBI in ovarian cancer
could facilitate the generation of new drugs that re-sen-
sitize tumor cells to paclitaxel [4].
In this study, we examined the methylation status and
expression of TGFBI in epithelial ovarian cancer tissues,
paclitaxel-sensitive and -resistant ovarian cancer cell
lines in order to determine whether the methylation of
TGFBI is asscociated with paclitaxel chemoresistance.
Materials and methods
Ovarian cancer tissue samples and cell lines
From April 2008 to April 2009, 40 primary epithelial
ovarian cancer(, 10 benign tumor and 10 normal ovarian
tissues) were collected at the Department of Obstetrics
and Gynecology, The Affiliated Hospital of Medical Col-
lege, Qingdao University, China. The mean age of the
patients was 43 years (range 21-77 years). The ovarian
cancer patients have different histological types: serous
papillary carcinoma (n = 20), mucinous carcinoma (n =
13), endometrioid carcinoma (n = 7). Six patients were
in stage I, ten patients were in stage II, twenty-four
patients were in stage III. Twenty-two patients had
metastasis to pelvic lymph nodes. Eleven tumors were
well-moderately differentiated, and 29 tumors were
poorly differentiated. Ten benign tumor and 10 normal
ovarian tissues were collected as control. All samples
were obtained prior to chemotherapy or radiation ther-
apy, which were placed in liquid nitrogen immediately
after resection and stored at -80°C until use. The malig-
nant and normal diagnosis was performed by patholo-
gists. The study was performed after approval by our
institute Medical Ethics Committee.
Human SKOV3, A2780 and OVCAR8 ovarian cancer
cell lines were obtained from the bioengineering centre
of The Affiliated Hospital of Medical College, Qingdao
University, China. The chemoresistant cell lines (SKOV3/
DDP, SKOV3/TR, and A2780/TR) were purchased from
the China Center for Type Culture Collection (Wuhan,
China). These cells were maintained in DMEM with 10%
fetal bovine serum and 100 U/ml penicillin/streptomycin
at 37°C. SKOV3/TR and A2780/TR were cultured in
RPMI-1640 medium containing 0.3 μmol/L paclitaxel to
maintain the drugresistant phenotype.
Cells were grown to 70% confluence and treated with
10 μmol/L of demethylating agent (5-aza-2’-deoxycyti-
dine, 5-aza-dc) (Sigma-Aldrich, St. Louis, MO, USA) for
3 days [22]. After the treatment, cells were harvested
and extracted for DNA, RNA and protein.
Nucleic acid isolation
The EZNA Tissue DNA Kit (Omega Corp, USA) was used
to extract high purity DNA from different ovarian tissues
and ovarian cancer cell lines. Total DNA content was
quantified by UV absorbance value measured at A260 and
A280, and diluted to a concentration of 1 μg/100 μl.
Methylation-specific PCR (MSP) and bisulfite sequencing
PCR (BSP)
DNA from tissue samples and cell lines were subjected
to bisulfite treatment using CpGgenome DNA Modifica-
tion Kit (Chemicon, USA). Sequences, Tm, and product
length of each primer used for MSP and BSP analysis
are summarized in Table 1 The band expanded with
methylation-specific PCR primers corresponding to the
DNA methylation in the promoter region was marked
as “M”. The band expanded with non-methylation-speci-
fic primers was marked as “U”.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cells with Trizol reagent
(Invitrogen, San Diego, CA, USA), and it was reverse
Table 1 Sequences of Primers for MSP and RT-PCR
Gene Primer Sequences Temp (°C) Length(bp)
TGFBI M-F 5’-gAAAATTGAGTACGGGTATAGTGC-3’ 58 162
M-R 5’-CCAAATTAAATAAACTACGAACGAA-3’
U-F 5’-AAAATTGAGTATGGGTATAGTGTGG-3’ 56 161
U-R 5’-CCAAATTAAATAAACTACAAACAAA-3’
B-F 5’-TGGAAGTAGTTATAGGAGGTTTAAGG-3’ 55 402
B-R 5’-CCCAAAACCAAAACCAAAAC-3’
qRT-F 5’-GGCTGCAGAGTCTGATGTGT-3’ 55 81
qRT-F 5’-CGCTCACTTCCAGAGAGATG-3’
GAPDH qRT-F 5’-GGACCTGACCTGCCGTCTAG-3’ 55 99
qRT-R 5’-TAGCCCAGGATGCCCTTGAG-3’
M: methylated primers [23], U: unmethylated primers [23], B: primers of BSP primers (designed using MethPrimer), qRT, primers of Quantitative Real-Time PCR.
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(Qiagen, Hilden, Germany). The primers for mRNA are
listed in Table 1. The quantification was performed with
QuantiTect Probe RT-PCR (Qiagen, Hilden, Germany).
The comparative threshold cycle method was used to
determine gene relative expression.
Western blotting
Cells were washed twice with ice-cold phosphate-buf-
fered saline and lysed using a modified RIPA buffer sup-
plemented with 1 mM PMSF. The protein
concentration was detected using BCA protein assay
(Pierce, Rockford, IL, USA). Proteins were loaded onto
10% and 5% SDS-PAGE and electrophoretically trans-
ferred to a PVDF membrane (Millipore, Bedford, MA,
USA). After blocking with 5% non-fat milk in PBS-
Tween 20 for 2 h at room temperature, the membranes
were incubated with anti-human monoclonal b-actin
and anti-human TGFBI primary antibody overnight at
4°C. Horseradish peroxidase-conjugated secondary anti-
body was added for 2 h at room temperature. The
Detection was performed by chemiluminescence.
MTT assay
MTT Cell Proliferation Assay (Biosharp, USA) was used
to measure cell viability. Before and after treated with 5-
aza-dc, 1 × 10
4 cells/well were seeded in 96-well plates
containing complete medium and incubated for 24 h.
Then cells were exposed to serial dilutions of paclitaxel
in a total volume of 200 μL in four replicate wells. After
48 hours, plates were added 20 μl of MTT reagent and
incubated for 4 h, and then formazane crystals formed
were dissolved in 150 μlo fd i m e t h y ls u l f o x i d e( W a k o ,
Tokyo, Japan). The optical density was measured at 490
nm on a microplate reader. The half maximal inhibitory
concentration (IC50) value was assessed by different
concentrations of paclitaxel (0.01, 0.1 and 1 μM).
Statistical analyses
All statistical analyses were performed using SPSS 15.0.
Fisher’s exact test or and c
2 test were used to compare
TGFBI methylation status among cases and between
various clinicopathologic variables. Pearson correlation
analysis was used to evaluate the relationship between
TGFBI methylation status and mRNA expression. The
differences of TGFBI mRNA and protein expression
before and after 5-aza-dc treatment were analyzed by
the Paired-Samples t test. P < 0.05 was considered sta-
tistically significant.
Results
Frequency of TGFBI methylation in ovarian cancer tissues
We determined the frequency of TGFBI methylation in
40 primary ovarian cancer samples, 10 benign ovarian
tumors and 10 normal ovarian tissues by MSP (Figure
1). TGFBI in all of the normal ovarian tissues was com-
pletely methylation free, which showed success of DNA
modification. The overall frequency of methylation in
benign ovarian tumors was 10.0% (1/10). For ovarian
cancer tissues, 72.5% (29/40) of methylation was
observed. The data demonstrated that the difference of
TGFBI methylation frequency among ovarian cancers,
benign ovarian tumors and normal ovarian tissues was
statistically significant (P < 0.001).
The methylation status of the ovarian cancers was
compared with clinicopathological characteristics from
these patients including age, histological type, tumor
stage, histological grade and lymphatic metastasis. No
significant correlation between TGFBI methylation and
any of these parameters was observed for the ovarian
cancer patients (Table 2).
Expression of TGFBI mRNA in ovarian cancer tissues
To examine whether TGFBI methylation results in the
suppression of TGFBI expression, we examined TGFBI
mRNA expression by qRT-PCR in 40 ovarian cancer tis-
sues and 10 normal ovarian tissues. TGFBI mRNA expres-
sion was detected in all the normal ovarian tissues (10/10)
and in most of the unmethylated ovarian cancer tissues
(10/11). In contrast, TGFBI expression was not detected in
the TGFBI-methylated ovarian cancer tissues (27/29),
except for 2 tissues. We compared the TGFBI mRNA
expression results of these ovarian cancer tissues with the
TGFBI methylation data and found a significant correla-
tion between TGFBI methylation and loss of TGFBI
Figure 1 Methylation status of TGFBI in ovarian cancer, benign
ovarian cancer and normal ovarian cancer tissues. Three
carcinomas had completely methylated TGFBI genes, while 2
benign and 2 normal cases showed no methylation. DL: Marker
DL2000; T1, T2, T3: ovarian cancer tissues; B1, B2: benign ovarian
tissues; N1, N2: normal ovarian tissues.
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the inactivation of TGFBI expression is closely correlated
with gene methylation in ovarian cancer tissues.
Demethylation and re-expression of TGFBI after treating
with 5-aza-dc in ovarian cancer lines
We detected the methylation status of TGFBI promoter
region in 4 ovarian cell lines by MSP and BSP before and
after treating with 5-aza-dc. Before treatment, there was
partial TGFBI methylation detected in SKOV3 and
A2780 cells (42.9% and 35.2% of total CpG sites, respec-
tively). In contrast, almost complete hypermethylation
were found in SKOV3/TR (94.3% of total CpG sites) and
A2780/TR (91.4% of total CpG sites) cells (Figure 2).
After 5-aza-dc treatment, a “U” band appeared while
the “M” band did not disappear in A2780/TR cell line,
w h i c hd e m o n s t r a t e dt h a tt h emethylation was partially
reversed. In another cell line SKOV3/TR, the “M” band
disappeared and only a “U” band was left, indicating
that the methylation had been completely reversed (Fig-
ure 3).
The expression of TGFBI mRNA was examined in all
the 6 ovarian cancer cell lines by qRT-PCR before and
after treating with 5-aza-dc (Figure 4). Our data showed
that the relative expression of TGFBI mRNA increased
significantly after treating with 5-aza-dc in SKOV3/TR
(7.8 ± 0.9 vs. 0, P < 0.001) and A2780/TR (6.4 ± 0.2
vs.0, P < 0.001) cells. However, no statistical differences
of relative TGFBI mRNA expression were found after 5-
aza-dc administration in OVCAR8 (1.6 ± 0.3 vs. 0.8 ±
0.1, P> 0.05), SKOV3(5.1 ± 0.2 vs. 4.2 ± 0.2, P> 0.05),
SKOV3/DDP (1.4 ± 0.9 vs. 0.9 ± 0.2, P> 0.05) and
A2780 cells 2.7 ± 0.9 vs. 2.1 ± 0.7, P> 0.05).
In addition, we examined TGFBI protein (TGFBIp)
expression in all the cell lines by Western blotting (Fig-
ure 5). The data showed that the expression of TGFBIp
in SKOV3/TR and A2780/TR cell lines was statistically
up-regulated after 5-aza-dc administration (P < 0.01 and
P < 0.01, respectively). By contrast, no significant differ-
ences were found in other cell lines (all P > 0.05), which
was coincident with the results of qRT-PCR.
MTT assay
Further, we studied the effect of cell proliferation of 5-
aza-dc on paclitaxel-resistant cell lines by MTT viability
assay. Our results showed that the rate of cell inhibition
was significantly increased in SKOV3/TR and A2780/TR
than that in control groups at several paclitaxel
Table 2 Association of TGFBI methylation and
clinicopathologic variables in 40 ovarian cancer patients
Clinicopathologic
characteristics
Number
(n)
Methylation
(%)
P
value
Age at diagnosis
< 50 years 14 9 (64.3) 0.3932
≥50 years 26 20 (76.9)
Histological type
Serous adenocarcinoma 20 16 (80.0) 0.4814
Mucinous adenocarcinoma 13 9 (69.2)
Endometrioid adenocarcinoma 7 4 (57.1)
Tumor stage
I 6 2 (33.3) 0.0661
II 10 8 (80.0)
III 24 19 (79.2)
Histological grade
G1 4 2 (40.0) 0.5532
G2 7 5 (71.4)
G3 29 22 (75.9)
Lymphatic metastasis
No 18 13 (72.2) 0.9716
Yes 22 16 (72.7)
Figure 2 Bisulfite sequencing of SKOV3, SKOV3/TR, A2780 and
A2780/TR. Paclitaxel-resistant cell lines (SKOV3/TR and A2780/TR)
showed almost complete CpG methylation (91.4% and 97.1% of
total CpG sites, respectively), the sensitive cell lines SKOV3 and
A2780 showed partial methylation of CpG islands (42.9% and
35.24% of total CpG sites, respectively).
Figure 3 MSP analysis of TGFBI in paplitaxel resistant cell lines
after demethylation by 5-aza-dc. After 5-aza-dc treatment, a “U”
band appeared while the “M” band did not disappear in A2780/TR
cell line. In another cell line SKOV3/TR, the “M” band disappeared
and only a “U” band was left. DL: Marker DL2000; SKOV3/TR, A2780/
TR: before treatment; SKOV3/TR’, A2780/TR’: after treatment; U:
unmethylation, M: methylation.
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6). The IC50 of SKOV3/TR obviously decreased after 5-
aza-dc administration (0.19 ± 0.01 μMv s .0 . 4 2±0 . 0 2
μM, P = 0.001), which was similar with the results of
A2780/TR (0.012 ± 0.0001 μM vs. 0.33 ± 0.011 μM; P =
0.001).
Discussion
In this study, we first detected the methylation status of
the 5’ CpG island of TGFBI in different ovarian tissues
using MSP and BSP in order to determine whether
TGFBI inactivation by DNA methylation is characteristic
of human ovarian cancer. After repeated experiments,
our results showed that the TGFBI is frequently methy-
lated in ovarian cancer. Its methylation can be used as a
novel epigenetic biomarker for ovarian cancer detection.
We further measured TGFBI mRNA and protein
levels by RT-PCR and IHC in ovarian cancer tissues.
Then we compared the TGFBI expression results with
the TGFBI methylation data and found a significant
inverse correlation between TGFBI methylation and
TGFBI expression, which confirmed the important role
of promoter methylation in regulating TGFBI expres-
sion. However, because 1 ovarian cancer tissue lacking
TGFBI mRNA expression was not methylated, we pre-
sume that mechanisms of inactivating the gene other
than methylation must exist.
Recently, Shah et al. [20] reported that TGFBI methy-
lation was associated with tumor recurrence and metas-
tasis, suggesting that TGFBI is required to suppress the
aggressiveness of prostate and lung cancer. In our study,
the methylation rate of carcinomas with poor differen-
tiation was higher than those with well differentiation.
Meanwhile, higher methylation rate was also found in
late stage patients with ovarian cancers, though no sig-
nificant correlation was found between TGFBI methyla-
tion status and clinicopathological characteristics, which
was in accordance with the results of Kang et al [23].
Our results showed that there were different patterns of
mythylation according to the histology and the tumor
grade, and revealed that hypermethylation of TGFBI in
ovarian cancer might be associated with unfavourable
prognosis. Further studies with large sample size and
long-term follow-up are required to confirm the
hypothesis.
Chemoresistance is the major cause of treatment fail-
ure for ovarian cancer. It is reported that DNA methyla-
tion may act as a potential cause of chemotherapy drug
resistance [24-26]. In a recently study by Li et al. [27],
cisplatin-sensitive and -resistant ovarian cancer cells
were analyzed by methylation and mRNA expression
microarray. Their results revealed that DNA hyper-
methylation may contribute to the onset of the che-
moresistance in ovarian cancer.
In our study on cell lines, almost complete methyla-
tion pattern of the TGFBI promoter in 2 paclitaxel-
resistant cell lines (SKOV3/TR and A2780/TR) was
observed, with a complete loss or low level of TGFBI
expression in these cell lines. In contrast, only sparsely
methylated or unmethylated CpG sites were identified
in cell lines with a rich level of TGFBI expression,
including SKOV3, A2780, OVCAR8, and SKOV3/DDP
ovarian cancer cell lines. Our results identified strong
relation between TGFBI expression and response to
Figure 5 The TGFBIp expression before and after treatment of
5-aza-dc by Western blotting. Expression of TGFBIp in SKOV3/TR
and A2780/TR cell lines was sharply up-regulated after treatment of
5-aza-dc. A2780, SKOV3, A2780/TR, SKOV3/TR: before treatment;
A2780’, SKOV3’, A2780/TR’, SKOV3/TR’: after 5-aza-dc treatment.
Figure 6 Demethylation of TGFBI restores the sensitivity of
paclitaxel-resistant ovarian cells. The inhibition rates in paclitaxel-
resistant cells with 5-aza-dc treatment were increased significantly
than control ones (* P < 0.05; ** P < 0.01).
Figure 4 Quantitative real-time RT-PCR analysis of TGFBI
expression in ovarian cancer cells. It showed that the relative
expression of TGFBI mRNA increased significantly after treating with
5-aza-dc in SKOV3/TR and A2780/TR cells. However, no statistical
differences of relative TGFBI mRNA expression were found after 5-
aza-dc administration in other cell lines.
Wang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:6
http://www.jeccr.com/content/31/1/6
Page 5 of 6chemotherapy. To our knowledge, this is the first evi-
dence of TGFBI hypermethylation as a mechanism of
paclitaxel chemoresistance in ovarian cancer.
Further, our results were confirmed by using DNA
methylation inhibitors. The relative expression of TGFBI
mRNA and protein increased significantly after treating
with 5-aza-dc in palitaxel-resistant cells. However, no
statistical differences of TGFBI expression were found
after 5-aza-dc administration in other 4 cell lines. In
addition, MTT assay showed that the rate of cell inhibi-
tion was significantly increased in SKOV3/TR and
A2780/TR after 5-aza-dc treatment, which suggested
that chemotherapy sensitivity to paclitaxel was enhanced
and chemoresistance was reversed.
In conclusion, our study indicated that promoter
hypermethylation of TGFBI is a frequent event in ovar-
ian cancer. TGFBI methylation was associated with
paclitaxel chemoresistance, and it can be used as a
potential epigenetic biomarker and therapeutic target of
paclitaxel resistance in ovarian cancer.
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